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Although Rett syndrome (RTT) represents one of the most frequent forms of severe
intellectual disability in females worldwide, we still have an inadequate knowledge of
the many roles played by MeCP2 (whose mutations are responsible for most cases
of RTT) and their relevance for RTT pathobiology. Several studies support a role of
MeCP2 in the regulation of synaptic plasticity and homeostasis. At the molecular
level, MeCP2 is described as a repressor capable of inhibiting gene transcription
through chromatin compaction. Indeed, it interacts with several chromatin remodeling
factors, such as HDAC-containing complexes and ATRX. Other studies have inferred
that MeCP2 functions also as an activator; a role in regulating mRNA splicing and
in modulating protein synthesis has also been proposed. Further, MeCP2 avidly binds
both 5-methyl- and 5-hydroxymethyl-cytosine. Recent evidence suggests that it is the
highly disorganized structure of MeCP2, together with its post-translational modifications
(PTMs) that generate and regulate this functional versatility. Indeed, several reports have
demonstrated that differential phosphorylation of MeCP2 is a key mechanism by which
the methyl binding protein modulates its affinity for its partners, gene expression and
cellular adaptations to stimuli and neuronal plasticity. As logic consequence, generation
of phospho-defective Mecp2 knock-in mice has permitted associating alterations in
neuronal morphology, circuit formation, and mouse behavioral phenotypes with specific
phosphorylation events. MeCP2 undergoes various other PTMs, including acetylation,
ubiquitination and sumoylation, whose functional roles remain largely unexplored. These
results, together with the genome-wide distribution of MeCP2 and its capability to
substitute histone H1, recall the complex regulation of histones and suggest the relevance
of quickly gaining a deeper comprehension of MeCP2 PTMs, the respective writers and
readers and the consequent functional outcomes.
Keywords: chromatin, MeCP2, mouse models, phosphorylation, post-translational modifications, Rett syndrome,
synaptic plasticity
INTRODUCTION
Rett syndrome (RTT) is a devastating disorder that, because of its
incidence, is considered one of the main causes of severe intel-
lectual disability in girls (Percy and Lane, 2005). Typical RTT
patients appear to develop normally throughout the first 6–18
months of life when neurological development arrests and a
Abbreviations: MeCP2, methyl-CpG binding protein 2; RTT, Rett syndrome;
PTM, post-translational modification; MBD, methyl-DNA binding domain; TRD,
transcriptional repression domain; ID, intervening domain; NTD, N-terminal
domain; CTD, C-terminal domain; 5hmC, 5-hydroxymethyl cytosine; pMeCP2,
phosphorylated MeCP2; ChIP, chromatin immunoprecipitation; KI, knock-in;
MS, mass spectrometry; LTP, long-term potentiation; Ub, ubiquitination; Met,
methylation, SUMO, sumoylation; Ac, acetylation; O-GlcNAc, O-glycosylation.
regression phase occurs leading to the loss of previously acquired
skills. During and after the regression phase, patients develop a
host of typical symptoms including the substitution of purpose-
ful hand use with continuous stereotypic handmovements, loss of
language skills, the appearance of autistic features, gait abnormal-
ities, breathing irregularities, seizures, scoliosis, hypotonia, and
autonomic dysfunctions (Neul et al., 2010).
Back in 1999, the Methyl-CpG binding Protein 2 (MECP2)
gene was discovered as the genetic cause of Rett syndrome (Amir
et al., 1999); since then, hundreds of different mutations of
the gene have been associated with RTT and less frequently
with other forms of intellectual disabilities, such as autism,
schizophrenia, mental retardation and Angelman-like syndrome
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(Chahrour and Zoghbi, 2007). Lately, duplication and triplica-
tion of the gene have also been identified as the genetic cause
of the recently classified MECP2 duplication syndrome that usu-
ally affects boys (Van Esch, 2011). The production of several
mouse models, carrying different Mecp2 alterations and pheno-
typically copying many typical features of the human disease,
has indeed provided the formal genetic proof of the involve-
ment ofMECP2 in RTT (Ricceri et al., 2008). Importantly, mouse
models of Mecp2 functions have also permitted to demonstrate
that phenotypic rescue is possible at least in mice, suggesting
that the MECP2-related conditions might be reversible (Guy
et al., 2007). These studies have dramatically boosted the research
of MeCP2 functions, and have yielded a wealth of evidence
proving that MeCP2 functions are required for the maturation
and maintenance of proper dendritic arborization and spine
formation. Thus, RTT pathogenic mechanisms appear to con-
verge at the synaptic level, disrupting synaptic transmission and
plasticity.
At a molecular level, there exist more contradictory data. In
fact, MeCP2 appears as a multifunctional protein, mainly but not
exclusively involved in regulating gene expression. It appears that
the structure of MeCP2 together with a series of differential post-
translational modifications (PTMs) might justify this functional
versatility, possibly occurring through the capacity of the methyl-
binding protein to interact with several diverse protein partners
(Klose and Bird, 2004). Thus, in this review we will briefly sum-
marize the animal models of Mecp2 that have been instrumental
for studying Rett syndrome. We will then describe relevant evi-
dence substantiating the functional importance of MeCP2 in
synaptic and neuronal plasticity regulation. Since we are cer-
tain that the development of well-targeted therapies requires a
better comprehension of the functional role(s) of MeCP2, their
regulation and their relevance in the pathobiology of RTT, we
will analyze in depth the current knowledge of MeCP2 structure
and molecular functions and provide bioinformatics and exper-
imental data testifying already established and putative PTMs
of MeCP2. Functional studies and animal models used to char-
acterize some of these PTMs will be surveyed, highlighting the
major weaknesses in the field and which, in our mind, should
be the future challenges for a better comprehension of MeCP2
activities.
Mecp2 MOUSE MODELS RECAPITULATE WELL THE HUMAN
MECP2-RELATED PATHOLOGIES
The generation of several mouse models carrying different
Mecp2 alterations and generally recapitulating many RTT features
has provided a major breakthrough for RTT research (Ricceri
et al., 2008). In particular, the mostly used Mecp2-null males
(Mecp2−/y) have no apparent phenotype until 3–8 weeks of age,
when they start showing gross abnormalities, such as locomo-
tor defects, hindlimb clasping, hypotonia, reduced spontaneous
movements, tremors, breathing irregularities and often seizures.
Symptoms worsen over time, and the animals die within 6–
10 weeks of age. Heterozygous female mice (Mecp2−/+) are
viable, fertile and appear normal up to 4–6 months of life, when
they start manifesting RTT-like symptoms. Other models with
less severe genetic lesions, often mimicking human mutations,
have subsequently been generated, and are nicely reviewed in
Ricceri et al. (2008). Knock-in mice, used to address the role
of specific events of MeCP2 phosphorylation, are discussed in
SectionMeCP2 Phosphorylation:WhereWe Stand andWhereWe
Might Go.
The Mecp2308/y mice, expressing a hypomorphic MeCP2
pathogenic derivative, have also been widely utilized. The muta-
tion causes a deletion of the C-terminal portion, but spares the
two most relevant functional domains, i.e., the methyl-binding
domain and the transcriptional repression domain (see Section
MeCP2 Functions Depend on the Highly Structured Methyl-
binding Domain Embedded in a Disorganized Protein). Even
though the overall phenotype is milder, the Mecp2308/y mouse
model shares most of the features characterizing the knock-out
animals, including learning and memory deficits (Shahbazian
et al., 2002).
Conditional knock-out mice have also been generated and
characterized, in order to understand better the etiology of RTT
and the role of Mecp2 in discrete brain regions or cell types. As
reviewed in Na et al. (2013), the inactivation of Mecp2 in sin-
gle brain areas or neuronal subtypes generally leads only to a
subset of the typical RTT features. Importantly, despite the fact
that all Mecp2 mutations investigated so far affect brain func-
tions, they are not associated with neuronal loss. Consistently, a
major breakthrough in the field came in 2007, when Dr. Bird and
his collaborators demonstrated that Mecp2-reactivation in symp-
tomatic adult mice (either Mecp2−/y or Mecp2−/+) results in a
robust rescue of the general conditions of the animals, including
survival and breathing, while mobility, clasping, and tremors were
less reversed. Altogether, these studies demonstrated that Mecp2-
related disorders are reversible and, at least in mice, they can be
treated even at late stages of disease progression (Guy et al., 2007).
Importantly, these results have been confirmed by several other
subsequent studies (Luikenhuis et al., 2004; Giacometti et al.,
2007; Jugloff et al., 2008; Garg et al., 2013).
In spite of these recent enormous advances, we highlight
that the knowledge regarding the temporal steps through which
the consequences of dysfunctional MeCP2 start to manifest is
still limited. In fact, most of the studies have been performed
in the so-called pre-symptomatic (3–6 weeks of age) or symp-
tomatic (adult) animals. However, recent experimental results
have demonstrated that the inactivation of Mecp2 at differ-
ent post-natal ages (from late juvenile to adult) always causes
the appearance of RTT-like phenotypes and premature death
(McGraw et al., 2011; Cheval et al., 2012; Nguyen et al., 2012).
These results demonstrate that MeCP2 functions are essential to
maintain neurons in a fully functional state. Conversely, it has
recently been shown that subtle but consistent impairments are
present even at early post-natal stages, when typical symptoms are
not yet overt, both in human heterozygous patients and hemizy-
gous null mice. Furthermore, hemizygous MECP2 male patients
display a severe pathological condition as early as at birth (Schüle
et al., 2008). Thus, considering that very few studies investi-
gated the possible roles of Mecp2 during embryonic development
(Picker et al., 2006; Santos et al., 2007; De Filippis et al., 2010),
we underline the necessity to foster the comprehension of MeCP2
functions also during brain development.
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MeCP2 ALTERATIONS LEAD TO A SYNAPTIC PHENOTYPE
Once the relevance of MeCP2 had been demonstrated for the
central nervous system, it became imperative to define the expres-
sion pattern of the protein during brain development and the
associated neuro-pathological abnormalities.
Concerning MeCP2 protein levels, it is generally accepted that
its expression in brain mirrors neuronal maturation. That is,
MeCP2 increases when neurons develop dendritic arbors, project
axons and establish connectivity (Kishi and Macklis, 2004; Neul
and Zoghbi, 2004). Interestingly, MeCP2 has been shown to be
present in an experimental model that prevents synapse forma-
tion, albeit at lower level than normal, suggesting that the abun-
dance of MeCP2, rather than its presence, depends on synapse
formation (Neul and Zoghbi, 2004).
Altered MeCP2 expression and activity do not affect the gross
structure of the brain, and no obvious signs of degeneration,
gliosis or inflammation have been reported in RTT patients
(Chahrour and Zoghbi, 2007). The most conspicuous morpho-
logical abnormalities in post-mortem RTT patients are reduced
brain size and weight, with more subtle alterations, such as
reduced dendritic arborization, defects in spine density and mor-
phology, and an increase in neuronal packing, in turn leading
to augmented cellular density (Bauman et al., 1995; Belichenko
et al., 2009b). Abnormalities in the expression of molecules, such
as NMDA, AMPA and GABA receptors, that are crucial for both
excitatory and inhibitory synaptic transmission, have also been
detected (Johnston et al., 2005). Mouse models of RTT have
demonstrated similar defects. In particular, two elegant works
from Belichenko et al. (2009a,b) have shown that most of the
parameters analyzed were altered in dendrites of Mecp2-mutant
mice of both genders. In particular, and most strikingly, den-
drites were swelled, spine density was altered (generally reduced,
but increased in few brain areas), and a smaller head and a
longer neck characterized the spines. Overlapping results were
obtained observing hippocampal neurons of female RTT patients
(Chapleau et al., 2009). Furthermore, neurons generated in vitro
from induced pluripotent stem cells (iPSCs) derived from RTT
patients’ fibroblasts showed lower dendritic spine density than
control neurons (Moutri et al., 2010).
Taken together, all these findings have led to the hypothe-
sis that the neurological deficits of RTT patients arise because
of a failure in synaptic and circuit development and/or main-
tenance. Accordingly, a number of studies have shown that
Mecp2-null hippocampal slices are characterized by significantly
reduced spontaneous excitatory synaptic transmission, deficits in
long-term potentiation (LTP), and long-term depression (LTD).
Furthermore, 2-photon time lapse imaging has shown that, at the
onset of the disease, Mecp2-null somatosensory cortices display
remarkable alterations in the dynamics of dendritic spines; on
the contrary, when maturation of the connectivity is complete,
no differences in spine dynamics are evident in Mecp2-mutant
mice with respect to their wild-type controls (Landi et al., 2011).
Accordingly, it has also been demonstrated that dendritic spine
density of hippocampal CA1 pyramidal neurons is lower only at
postnatal day 7 (P7), while it does not differ at P15 or later, when
symptoms are already well-established (Chapleau et al., 2012).
These data support a role of Mecp2 during early development
of dendritic spines and suggest that, at least in the Mecp2-null
mouse model used in these studies, compensatory mechanisms
that normalize spine density might occur later on in develop-
ment. However, it is important to observe that a different study,
performed using two diverse Mecp2-null lines, reported lower
dendritic spine density in hippocampal neurons of animals of 3
weeks of age (Belichenko et al., 2009a). We believe that in the
future it will be relevant to address these topics using models of
the disease, which are less severe and mimick pathogenic human
mutations. Furthermore, similar studies should include both gen-
ders: in fact, considering that RTT predominantly affects girls,
it is reasonable to assume that heterozygous females represent
the appropriate genetic mouse model of Rett syndrome, whereas
Mecp2-null male mice can be considered a suitable model for
addressing the biological function of the Mecp2 gene.
Finally, evidence is accumulating that overexpression of
MeCP2 also affects neuronal plasticity: indeed, decreased den-
dritic branching and spine density, enhanced excitatory synaptic
transmission and altered glutamatergic transmission have been
associated with mouse models of the so-called MECP2 duplica-
tion syndrome. Enhanced hippocampal LTP responses have been
demonstrated in Mecp2 overexpression mouse lines with respect
to their littermate controls (Na et al., 2013).
To conclude, a wealth of evidence now substantiates the func-
tional importance of MeCP2 in the regulation of dendritic struc-
ture, synaptic plasticity and homeostasis, therefore providing a
rationale for the learning and memory deficits that are consti-
tutively seen in RTT patients and in the mouse models of the
disease.
MeCP2 FUNCTIONS DEPEND ON THE HIGHLY STRUCTURED
METHYL-BINDING DOMAIN EMBEDDED IN A
DISORGANIZED PROTEIN
Starting from the previous observations, we believe that the devel-
opment of clinical applications implies the urgency of improving
our understanding of the functional roles of MeCP2, their regula-
tion, and the protein domains involved. Thus, we will now review
the state of art of MeCP2 structure and function.
MeCP2 has originally been described as an abundant and
ubiquitously expressed nuclear protein that binds selectively
methylated DNA (Lewis et al., 1992). In this first work, the
primary structure of the human protein was defined as a polypep-
tide 486 residues long, containing two main domains, namely, a
methyl-CpG binding domain (MBD) and a transcription repres-
sion domain (TRD). Nowadays, we know that alternative splicing,
occurring both in human and mouse, generates two main iso-
forms of the protein (MeCP2_e1 and MeCP2_e2; Figure 1A;
Chahrour and Zoghbi, 2007). Considering that (i) the primary
structure of MeCP2 is highly conserved among vertebrates, (ii)
the two principal isoforms differ exclusively in the very first N-
terminal residues, and (iii) RTT mutations generally refer to the
MeCP2_e2 isoform, in this review, we will mainly refer to the
humanMeCP2_e2 isoform (486 residues; Figure 1A). However, it
is important to recall that MeCP2_e1 is the predominant isoform
in brain. Furthermore, sinceMeCP2 PTMs have been investigated
almost exclusively in rodents, in the future, it will be important
to address which of the identified PTMs are maintained in the
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FIGURE 1 | MeCP2 isoforms and pathogenic mutations. (A) Two MeCP2
isoforms, MeCP2_e1 and MeCP2_e2, are generated by alternative splicing
originating two distinct N-terminal regions. MeCP2_e1 is 498 amino acids
long and contains a N-terminal domain (NTD, yellow) of 90 amino acids of
which the first 21 are distinct, whereas MeCP2_e2, formed by 486 amino
acids, has 9 unique amino acids in its NTD (blue). MeCP2 is constituted by five
sub-domains: NTD, MBD (methyl-CpG binding domain), ID (intervening
domain), TRD (transcriptional repression domain, CTD (C-terminal domain);
below the MeCP2_e2 isoform is shown the amino acid numbers of the
different domains. (B) Schematic illustration showing the localization and the
frequency of pathogenic missense mutations within MeCP2. The small inset
shows in details the mutation frequency between 0 and 1%. The colors of the
vertical bars correspond to the color code of the distinct MeCP2 subdomains.
(C) Localization and frequency of non-sense and truncatingMECP2 mutations.
Frameshift mutations are shown in blue and non-sense mutations in red. The
small inset shows in details the mutation frequency between 0 and 1%.
human protein and whether human MeCP2 is characterized by
additional events of modification.
As of today, MeCP2 has been subdivided into five main
structural domains corresponding to the N-terminal domain
(NTD), the MBD, the intervening domain (ID), the TRD and
the C-terminal domain (CTD; Figure 1A). The MBD was orig-
inally defined as the minimum continuous ensemble of MeCP2
residues necessary and sufficient for selective binding to methy-
lated CpG-dinucleotides (Nan et al., 1997). Its relevance for
MeCP2 functions is highlighted by the fact that almost half of
the known disease-causing missense mutations in MECP2 occurs
within this domain, including three of the eight most frequent
RTT mutations (Figure 1B; for a complete updated database of
MECP2 mutations see www.Mecp2.chw.edu.au). In vitro studies
have confirmed the relevance of MeCP2 binding to methylated
DNA, suggesting that most, if not all, missense mutations within
the methyl-binding domain impair the selectivity of MeCP2
for methylated DNA (Yusufzai and Wolffe, 2000). The X-ray
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structure of the MBD alone or associated with methylated DNA
unexpectedly revealed that the MBD recognizes the hydration of
the major groove, in which methylated DNA resides, rather than
cytosine methylation per se (Ho et al., 2008). Importantly, these
studies have been extended by the recent demonstration that the
MBD of MeCP2 avidly binds both 5-methyl cytosine (5mC) and
5-hydroxymethyl cytosine (5hmC). This property has not been
observed for the other members of the MBD family (MBD1-4).
Interestingly, the pathogenic R133C MeCP2 mutant retains most
of its binding to methylated DNA, but has lost affinity for 5hmC.
Since small changes in theMBD structure seemed to influence the
DNA binding properties of MeCP2, the authors proposed that
PTMs affecting MeCP2 might alter its substrate specificity and,
thus, its downstream functions (Mellen et al., 2012). In possible
accordance with this hypothesis, the MBD has been found to be
phosphorylated, methylated and acetylated (see more ahead and
Figures 2, 3 and Supplementary Table 1). Interestingly, two lysine
residues (K130 and K135) surrounding R133 have been found
to be ubiquitinated (Gonzales et al., 2012). Although we do not
yet know whether these residues are mono- or polyubiquitinated,
several pieces of evidence prove that ubiquitin is a bulky mod-
ifier with possible direct steric effects on any modified protein,
influencing conformational flexibility and protein-protein inter-
actions. These studies thus suggest that ubiquitination might be a
mechanism for a direct and rapid control of MeCP2 activities and
interactions (Chernorudskiy and Gainullin, 2013). In the future,
it would be interesting to address whether acetylated K130 and
K133 affect the binding of MeCP2 to modified DNA.
The TRD was originally defined as the smallest region of
MeCP2 required for transcriptional repression in functional
assays (Lewis et al., 1992). No structural information is avail-
able for this domain or for the other remaining parts of MeCP2.
The lack of structural information can easily be explained by
Circular Dichroism studies and theoretical predictions demon-
strating that almost 60% of MeCP2 is unstructured (Adams et al.,
2007). Thus, MeCP2 is now recognized as an “intrinsically disor-
dered protein” that might acquire local secondary structures upon
binding to other macromolecules. Accordingly, MeCP2 is capa-
ble of multiple protein–protein interactions (Ausió et al., 2014;
Bedogni et al., 2014) and appears to enter into a stable association
with its cofactors only when bound to DNA. Thus, MeCP2 seems
to act as a multifunctional factor that sustains interactions with
specific partners depending on the architecture of its target DNA
sequences (Klose and Bird, 2004). Recent findings, which will be
discussed in details further on, suggest that also MeCP2 PTMs
affect its protein-protein interactions. It is relevant that several of
the modifications identified so far cluster in the transcriptional
repression domain (Figure 2).
Protease digestion has been used to define the remaining NTD,
ID and CTD domains (Adams et al., 2007); importantly, by
analyzing the MeCP2 mutation database, we found that almost
25% of residues in the CTD and ID have been associated with
pathogenic missense mutations, therefore suggesting their rele-
vance for MeCP2 functions (Figure 1B; Bedogni et al., 2014).
Although these two domains maintain a highly disorganized
structure, the ID domain has been involved in several protein-
protein interactions and diverse phosphorylation events (Bedogni
et al., 2014 and Figure 2). On the contrary, to the best of
our knowledge, the CTD has been found associated exclusively
with Sdccag1, a mediator of nuclear export (Long et al., 2011).
However, this domain, which is crucial for the binding of MeCP2
to chromatin, is subject to various modifications (Nikitina et al.,
2007; Bedogni et al., 2014).
To summarize we can state that: (i) the highly disorganized
structure of MeCP2 endows the protein with multiple functions;
(ii) the structured MBD gives the protein its unique capabil-
ity of interacting with both methylated and hydroxymethylated
DNA; (iii) PTMs of MeCP2 are likely to affect directly its bind-
ing to DNA and protein partners, therefore contributing to the
versatility of MeCP2.
MeCP2: THE COMPLEXITY OF A FUNDAMENTAL
MULTIFUNCTIONAL PROTEIN
Adrian Bird and collaborators originally identified MeCP2 as a
nuclear factor capable of binding DNA with at least one sym-
metrically methylated CpG-dinucleotide (Lewis et al., 1992) and
repressing transcription mainly through its TRD (Nan et al.,
1997). In this pioneering work the authors proposed that the
extent of MeCP2 repression depends on its abundance in the
nucleus, and that MeCP2 is capable of displacing histone H1 from
chromatin to access its binding sites (Nan et al., 1997). A subse-
quent work demonstrated that MeCP2 uses its CTD to stabilize
and asymmetrically protect linker DNA, thusmimicking the asso-
ciation of histone H1 with chromatin (Chandler et al., 1999). The
capability of MeCP2 to play the role of an architectural chromatin
protein was further supported by a report showing that MeCP2
is a potent chromatin-condensing factor, functioning directly
without other corepressor or enzymatic activities (Georgel et al.,
2003). The authors demonstrated that depending on its molar
ratio to nucleosomes, MeCP2 assembles novel secondary and ter-
tiary chromatin structures regardless of DNA methylation; these
effects on large scale chromatin organization represent a good
explanation for its ability to repress in vivo transcription at a
distance.
A further link between the repressive activity of MeCP2 and
chromatin compaction was established by demonstrating that the
TRD binds to corepressor complexes (Sin3A and NCoR) with
histone deacetylase activities, and that transcriptional repression
of methylated DNA in vivo is partially relieved by the deacety-
lase inhibitor trichostatin A (Jones et al., 1998; Georgel et al.,
2003). Importantly, through the years other chromatin-related
partners of MeCP2 have been identified, such as Brahma, ATRX,
CoREST, c-Ski, and H3K9 histone methyltransferase (Nan et al.,
1998; Chahrour and Zoghbi, 2007; Bedogni et al., 2014).
All these results fit very well with more recent results demon-
strating that in mature neurons, where MeCP2 abundance cor-
responds roughly to one molecule every second nucleosome, the
protein is genome-wide bound, tracks methylated DNA, serves
as an alternative linker histone, and organizes a specialized chro-
matin structure, thus dampening overall transcriptional noise
(Skene et al., 2010; Guy et al., 2011). The effect on global genomic
architecture is outlined by a selective increase in histone acety-
lation, H1 levels and transcription of repetitive elements and
L1 retrotransposons in Mecp2-null neurons, but not in glia,
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FIGURE 2 | The phosphorylation signature of MeCP2. (A) All
experimentally determined phosphorylation sites of MeCP2. The numbering
corresponds to the hMeCP2_e2 isoform. (B) The probability score of
phosphorylation sites within MeCP2 identified in silico by GPs 2.0 and
NetPhos 2.0 confronted with experimentally determined sites; only residues
identified as phosphorylation sites in silico with P > 0.5 are listed. Further
details including references of experimentally determined sites are listed in
supplementary Table 1.
where the protein is much less abundant (Moutri et al., 2010;
Skene et al., 2010). Thus, the lack of functional MeCP2 in
mature neurons might lead to a disorganized chromatin structure
that impairs synaptic plasticity by preventing proper neuronal
responses to stimuli. Cohen et al. (2011) have then recently rein-
forced the possibility thatMeCP2 does not regulate the expression
of specific genes, but rather functions as a histone-like factor,
globally bound across the genome.
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FIGURE 3 | Post-translational modifications other than phosphorylation
affecting MeCP2. (A) Two PEST motives, enriched in proline, glutamate,
serine, and threonine residues, are present within MeCP2 possibly regulating
its stability and phosphorylation. (B) Schematic representation of the
different types of post-translational modifications (PTM) affecting MeCP2 and
the involved amino acids.
MeCP2 functions have been further expanded in the last years
and a role in facilitating gene expression has also been sug-
gested. In particular, the analysis of gene expression patterns in
the hypothalamus of mice that either lack or overexpress Mecp2,
led Huda Zoghbi and her colleagues to propose that MeCP2 pre-
dominantly activates transcription (Chahrour et al., 2008). The
authors suggested that the association of MeCP2 with the tran-
scriptional activator CREB1might explain these results. Similarly,
in a recent paper Rudolf Jaenisch and his collaborators demon-
strated that the reduced size of Mecp2-null neurons affects total
RNA levels per cell. By analyzing global transcriptional profiles
starting from an identical number of cells, thus avoiding the usual
normalization to total input RNA (Li et al., 2013), they found
more down-regulated than up-regulated genes, leading to the
conclusion that one of the key functions of MeCP2 is to facili-
tate global transcription. So far, the “per cell” perspective has been
used only in one report (Li et al., 2013) and we still need to under-
stand whether the discrepancy between the studies can be justified
by the different approaches. Further, we suggest, as described in
a recent publication, that higher-level bioinformatics, identifying
statistically significant deregulated molecular pathways (rather
than single genes), might allow the identification of the biolog-
ical processes affected by dysfunctional MeCP2 (Bedogni et al.,
2014).
In addition to all of this, it is important to recall that MeCP2
has also been proposed to play a role in regulating mRNA splic-
ing and in modulating protein synthesis. In fact, Mecp2 was first
found to interact with the RNA-binding protein Y box-binding
protein 1 (YB1) and to regulate splicing of reporter minigenes.
Supporting these data in vivo, aberrant alternative splicing pat-
terns were also observed in a mouse model of RTT (Young et al.,
2006; Maunakea et al., 2013). The involvement of MeCP2 in
mRNA biogenesis has been further proven by the interaction of
Mecp2 with Prpf3 (pre-mRNA processing factor 3), a spliceosome
associated protein (Long et al., 2011). Eventually, a severe defect
in protein synthesis in Mecp2 mutant mice was for the first time
demonstrated by Ricciardi et al. (2011). This deficiency, which is
a common defect in autism spectrum disorders, was ascribed to a
dysfunctional AKT/mTOR pathway. The relevance of these find-
ings has subsequently been strengthened by the demonstration
that pharmacological or genetic enhancement of protein synthesis
ameliorates Mecp2-defective neurons (Li et al., 2013).
Thus, considering the structural flexibility of MeCP2 and the
possibility of PTMs affecting its structure and/or interactions
with protein partners, we believe that a better comprehension
of MeCP2 functions might be obtained through the study of its
diversely modified isoforms and their networking capabilities.
Therefore, we will progress critically surveying the actual knowl-
edge on MeCP2 phosphorylation that so far certainly represents
the best characterized PTM of the methyl-binding protein.
MeCP2 PHOSPHORYLATION: WHERE WE STAND AND
WHERE WE MIGHT GO
The history of MeCP2 phosphorylation (pMeCP2) began in 2003
when two independent studies demonstrated that neuronal acti-
vation triggers a calcium-dependent phosphorylation of Mecp2
and the consequent release of the methyl-binding protein from
Bdnf promoter III, thereby facilitating transcription (Chen et al.,
2003; Martinowich et al., 2003). Several were the breaking news
of these publications although some of them still remain debated.
To begin with, these studies proposed for the first time that
Mecp2 is involved in the control of neuronal activity-dependent
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gene regulation through its PTMs, and that the deregulation of
this process might participate in the RTT pathology. As we will
see, this concept still remains valid and has been further strength-
ened by the development of Mecp2 phospho-defective transgenic
mice (Table 1). Furthermore, these findings suggested thatMecp2
might work as a dynamic and selective regulator of neuronal gene
expression.
The residue involved was then identified as serine 421 (S421
refers to mouse Mecp2_e2 and corresponds to S438 in Mecp2_e1
and S423 in hMeCP2_e2; see Figure 2); importantly, S421 phos-
phorylation occurs selectively in neural tissues and involves on
the average 10–30% of the overall Mecp2 molecules (Zhou
et al., 2006). By expressing a S421A phospho-defective deriva-
tive of Mecp2 in primary neurons, the authors demonstrated
that this PTM affects dendritic growth, whereas the impor-
tance of S421 phosphorylation for circuit development was sug-
gested by a defective patterning of distal apical dendrites in
the brain of a phospho-defective S421A knock-in (KI) mouse
line (Mecp2S421A/y, Cohen et al., 2011). Moreover, a shift in
excitation-inhibition balance in favor of inhibition in Mecp2
S421A cortical slices was measured (Table 1). The relevance of
S421 phosphorylation is emphasized by the fact that a simi-
lar shift has already been described in Mecp2 knock-out mice.
However, and possibly in accordance with the mild phenotype
of the KI mouse that appears to be defective only in the capabil-
ity of processing novel experience, so far no pathogenic mutation
has been associated with this residue. Of relevance, we still lack
insights regarding the molecular consequences of this PTM. As
already mentioned, initial data suggested that S421 phosphory-
lation induces the detachment from specific genes. However, a
ChIP-seq approach used to describe the genomic distribution of
this specific Mecp2 phospho-isoform in brain of knock-in mice
did not reveal a selective detachment of pMecp2 either in rest-
ing or stimulated conditions. These results might indicate that
Mecp2 affects activity-dependent transcription by changing the
molecular partners recruited on DNA (Chen et al., 2003).
By merging clinical data with those obtained from the S421A
KI mice, we speculate that S421 phosphorylation regulates only
some aspects of cognitive function, and that its deregulation leads
only to subtle cognitive impairments. Accordingly, the analysis of
the gene expression profiles did not reveal significant changes in
the expression of individual genes. However, a possible mild effect
on molecular pathways has not yet been addressed.
Importantly, S421 phosphorylation has also been associated
with drug sensitivity and mood regulation. In fact, the research
of stimuli affecting MeCP2 phosphorylation has led not only
Table 1 | Phosphorylation-defective Mecp2 mouse models.
Animal phenotype Synaptic physiology Molecular Phenotype Importance
Mecp2S80A;
Tao et al., 2009
Normal lifespan;
RTT-like phenotype;
-62% locomotor activity in
dark cycle running wheel
assays.
Decreased binding to
chromatin on specific gene
promoters.
S80 phosphorylation
regulates MeCP2 function in
resting neurons.
Mecp2T308A;
Ebert et al., 2013
Normal body weight;
Reduced brain weight;
More seizures and lower
seizure threshold;
Locomotor defects.
T308A mutation does not
alter MeCP2 stability, binding







interaction of MeCP2 with





Cohen et al., 2011
No visible differences




outlined with sociability and





No detectable effect on gene
transcription.
S421 phosphorylation has a








+145% locomotor activity in
dark cycle running wheel
assays;
Fear-conditioning test and
Morris water maze test
suggest an altered
hippocampus function.
Stronger LTP induced at both
the Schaffer collateral-CA1









show an increase in Bmp4
and Bdnf transcription and a
decrease in Mef2c and Grm1
transcription.
S421 phosphorylation is a
neuronal-activity induced
event.
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to demonstrate that hippocampus-dependent behavioral train-
ing leads to a robust increase in Mecp2 S421 phosphorylation (Li
et al., 2011), but also that a single acute injection of cocaine or
amphetamine elicits a transient increase in pS421 Mecp2 in the
caudate putamen and nucleus accumbens (Deng et al., 2010; Mao
et al., 2011). Having hypothesized that cellular and behavioral
adaptations to these drugsmight be affected by pS421, the authors
have very recently produced the first data demonstrating that
phosphorylation of MeCP2 at Ser421 functionally limits cellu-
lar sensitivity and synaptic response to repeated psychostimulant
exposure in the mesocorticolimbic circuitry (Deng et al., 2014).
A role for MeCP2 phosphorylation in the context of chronic
opioid consumption and withdrawal has also been suggested:
in fact, morphine withdrawal induces pS421Mecp2 in selected
brain areas, such as lateral septum and the nucleus accumbens
shell (Ciccarelli et al., 2013). Eventually, S421 phosphorylation
in the nucleus accumbens and lateral habenula has been associ-
ated with depressive-like behaviors: in fact, administration of the
antidepressant imipramine induces pS421Mecp2 and studies with
knock-in mice showed that this induction is required for a proper
response to the antidepressant (Hutchinson et al., 2012).
Mass spectrometry (MS) analysis identified that neuronal
activity induces also S424 phosphorylation in mouse brain (iso-
form 2; Tao et al., 2009). A KI mouse line, in which the phospho-
rylation at both residues of the endogenous protein is abolished,
was also generated (Mecp2S421A;S424A/y; Li et al., 2011). Before
reviewing the results obtained, it is worth mentioning that MS
failed to identify S424 phosphorylation in rat brain, therefore
questioning the possible involvement of this PTM in RTT. At the
molecular level, these two mutations did not affect the expres-
sion and intracellular localization of Mecp2; phenotypically, the
obtained mice did not show any overt difference with respect
to the wild-type animals. By exploiting conventional behav-
ioral tests, the authors found a higher performance for some
hippocampal functions, such as spatial memory, than in wild-
type littermates. In accordance with enhanced hippocampus-
dependent learning and memory, LTP was found significantly
stronger in Mecp2S421A;S424A/y hippocampal slices with respect to
the controls, together with an increase in excitatory synaptoge-
nesis in both cortical and hippocampal cultured neurons. ChIP
analyses permitted to hypothesize that the concomitant loss of
these two phosphorylation sites enhances the binding of Mecp2
to its target gene promoters; importantly, the transcriptional out-
come depends on the bound sequence, reinforcing the possibility
that MeCP2 can function both as an activator and a repressor of
transcription.
Summarizing the results obtained, both publications testify
that MeCP2 phosphorylation impacts the development and func-
tion of the nervous system. Furthermore, they suggest that
MeCP2 functions are regulated by several PTMs and their com-
bination. Future studies need to address whether a crosstalk
between MeCP2 PTMs exists, and moreover, the current contra-
diction concerning S424 phosphorylation needs to be solved. In
fact, Michael Greenberg reported as unpublished results that they
were unable to detect increased phosphorylation of Mecp2 S424
in response to neural activity both in vitro and in vivo (Cohen
et al., 2011). Thus, it is unclear whether the S424A mutation in
knock-in mice affects a phosphorylation site of Mecp2 or influ-
ences the molecular properties of the protein through an alterna-
tivemechanism. Although the production of a singleMecp2S424A/y
KI line might be informative, we are not confident it would be
convenient, also considering that so far this residue has never been
associated with RTT.
By surveyingMeCP2 phosphorylation in rat/mouse brains and
in human HeLa cells, Tao et al. (2009) found that S80 phospho-
rylation is the most conserved phosphorylation site of MeCP2.
S80 appears as the most abundantly phosphorylated residue
under resting conditions whereas neuronal activity induces its
dephosphorylation. Mecp2S80A/y knock-in mice are slightly over-
weight and show decreased locomotor activity (Tao et al., 2009).
Functionally, S80 phosphorylation does not affect the overall sub-
cellular localization of MeCP2, but seems to increase its affinity
for chromatin. However, these in vitro studies, together with
microarray analyses, were performed with exogenously expressed
MeCP2 derivatives, expressed at levels slightly above those of the
endogenous protein. Although no further data were produced
with this Mecp2 transgenic line, available information lead us to
suggest that S80 phosphorylation does not have any impact on
global transcription and that, probably, this MeCP2 phospho-
isoform is globally bound to chromatin, therefore resembling the
distribution of MeCP2 and the pS421 isoform.
A more recent work used phospho-tryptic maps to confirm
that Mecp2 is phosphorylated at many sites in cultured activated
and resting neurons (Ebert et al., 2013). In this study, the activity-
dependent phosphorylation of Mecp2_e2 occurs on residues S86,
S274, T308, and S421 (for an easier comprehension of the state
of art, all the so-far-identified MeCP2 phospho-sites are sum-
marized in Figure 2 and Supplementary Table 1). Considering
that the nearby R306 residue is mutated in RTT, and that its
pathogenic R306C mutation disrupts the ability of MeCP2 to
interact with the corepressor complex NCoR (Lyst et al., 2013),
the authors focused their attention on T308 phosphorylation
and found that it abolishes the interaction of MeCP2 with the
corepressor, thereby reducing MeCP2-mediated transcriptional
repression. The phospho-defective Mecp2T308A/y KI mice demon-
strated that mutant MeCP2 maintains its global distribution
on chromatin, but that activity dependent induction of MeCP2
target genes is deficient. Importantly, the brains of these mice
weigh significantly less, the animals display motor system defects,
and have a lower seizure threshold compared to wild-type mice.
Since all these symptoms recapitulate the manifestation of sev-
eral Mecp2 mouse models, this is a groundbreaking piece of work
highlighting not only the relevance of MeCP2 phosphorylation
but also its role as a transcriptional silencer through its interaction
with the corepressor complex NCoR/HDAC.
Eventually, the laboratory of Janine La Salle used SH-SY5Y
cells stably expressing FLAG-tagged mouse MeCP2_e1 to identify
MeCP2 PTMs by tandem mass spectrometry and, interestingly,
found them to cluster mainly in the MBD and TRD domains
(Gonzales et al., 2012). Regarding phosphorylation, six sites were
identified, partly overlapping with previous data (Figure 2). The
successful production of two phospho-specific antisera, against
pS80 and pS229, permitted to confirm that these modifications
are independent of one another, and can coexist on the same
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molecule of MeCP2 (Tao et al., 2009). Whereas both Mecp2
phospho-isoforms were found in brain and were characterized
by the same subnuclear distribution as total Mecp2, pS229Mecp2
showed enriched binding to a tested promoter with respect to
total Mecp2. Moreover, it was observed that pS80Mecp2 and
pS229Mecp2 have a preferential association with distinct com-
binations of MeCP2 cofactors compared to total MeCP2, con-
firming the hypothesis that MeCP2 changes its partners and
mechanisms of action through its PTMs. Accordingly, the phos-
phorylation of S80 seems to affect the interaction of MeCP2 with
RNA and the RNA-binding protein YB-1 (Gonzales et al., 2012).
Summarizing, most data suggest that MeCP2 is a multifunc-
tional protein that “transiently” performs its function(s) depend-
ing on its differential phosphorylation. Accordingly, although
S421 phosphorylation remains for the time being the most widely
characterized PTM and pT308 results as themost functionally rel-
evant, several other sites of phosphorylation have been mapped,
and their modification is often spatially regulated by specific stim-
uli. Almost no information is available so far on these PTMs
and their regulation during brain development; furthermore,
since a role of MeCP2 outside of the nervous system, particu-
larly in glia and microglia, has recently been demonstrated as
important for MECP2-related disorders, future studies should
also investigate MeCP2 phosphorylation in these cells. MeCP2
phosphorylation has been hypothesized to affect its binding to
target DNA sequences: however, no data seem to support this
hypothesis in neurons, and none of the phosphorylation events
characterized so far globally affect MeCP2 binding to chromatin.
It is highly plausible then that the identification and/or charac-
terization of novel phospho-residues of MeCP2 will lead to the
discovery of PTMs that generally or selectively influence its bind-
ing to chromatin. Furthermore, they should help providing a
better comprehension of MeCP2 in physiological and patholog-
ical conditions. To this purpose, we suggest that studies should
focus first on sites that are conserved by evolution and/or have
been found mutated in patients. Thus, we employed two different
tools to predict phosphorylation sites (GPs 2.0, Xue et al., 2008;
and NetPhos 2.0, Blom et al., 1999), at the same time screen-
ing the existent proteomic literature to reveal which residues have
already been foundmodified in cell lines or in vivo. The results are
summarized in Figure 2. Algorithms for the prediction of PTMs
in proteins are usually based on machine learning approaches,
and associate with the predictions a reliability score ranking the
residues according to their likelihood of being modified. The two
algorithms we employed yielded highly consistent results. All in
all, the strong correlation between experimentally verified phos-
phorylated sites and their ranking in the predictions leads us to
conjecture that sites with high prediction scores but not yet val-
idated, usually considered as “false positives,” might indeed be
very likely candidates for phosphorylation, and worth of further
experimental investigation.
Eventually, a thorough characterization of MeCP2 phospho-
rylation should also address which are the signaling pathways
involved, and the respective kinases and phosphatases. No phos-
phatases have been described yet: on the contrary, a few studies
(Chen et al., 2003; Martinowich et al., 2003; Zhou et al., 2006;
Bracaglia et al., 2009; Tao et al., 2009; Khoshnan and Patterson,
2012; Ciccarelli et al., 2013) have suggested kinases that either
directly or indirectly affect MeCP2 phosphorylation. Since the
data obtained so far do not appear as conclusive, and we con-
sider bioinformatics approaches not yet reliable enough to obtain
informative data on this aspect (data not shown), we have decided
not to address further this issue in this work.
MeCP2 POST-TRANSLATIONAL MODIFICATIONS OTHER
THAN PHOSPHORYLATION AND CONCLUSIONS
The heterogeneity of MeCP2 posttranslational modifications,
together with its genome-wide distribution (Skene et al., 2010),
its capacity to mediate the formation of a highly compacted chro-
matin structure in vitro (Georgel et al., 2003) and to substitute
histone H1 in vivo (Skene et al., 2010) have led some authors to
suggest that, when highly abundant, the protein might behave as
a specialized histone-like chromatin organizing factor. Thus, in
analogy with the histone code, it is highly conceivable, as already
hinted along this review, that MeCP2 PTMs affect its binding to
specific epigenetic marks as well as its interactions with protein
partners and therefore the resulting biological functions. In accor-
dance with this hypothesis, there are a few studies demonstrating
the existence on MeCP2 of PTMs different from phosphorylation
on MeCP2. Thus, in this last section we will briefly survey the
information existing so far. Available data are still very limited, no
animal models have been generated and, often, functional studies
have not been performed in neurons. Future studies will certainly
have to fill this gap of knowledge.
In detail, Gonzales et al. (2012) used SH-SY5Y cells stably
expressing epitope-tagged MeCP2_e1 to analyze its PTMs by tan-
dem mass spectrometry with 90% coverage. Importantly, apart
from the already mentioned phosphorylation events, 10 ubiqui-
tination sites were identified (Figure 3 and Table 2), with lysine
271 occurring as the most frequently modified site. Although,
no functional role has been yet provided for these PTMs, all of
them but two reside in the MBD or TRD domains leading to
the hypothesis that they might affect the binding of MeCP2 to
chromatin or its regulatory properties. These studies have been
performed in cultured cell lines and with exogenously expressed
MeCP2: however, their relevance might be underlined by the
fact that three of these sites have been associated to missense
mutations in RTT (Table 2). Eventually, by surveying literature
we found that lysine 130 had already been found ubiquitinated
(Wagner et al., 2011). The functional significance of ubiquitina-
tion is dual: generally, it is associated with the rapid degradation
of modified proteins; however, such modification can also have a
role in signaling or trafficking. Interestingly, Ausiò and his col-
laborators have identified two strong, conserved PEST motives
in the primary sequence of MeCP2 (Figure 3). PEST motives
are sequences enriched in proline, glutamate, serine, and threo-
nine residues, and often predispose proteins to rapid proteolytic
degradation (Thambirajah et al., 2009). The PEST structure gets
destabilized upon phosphorylation leading to the degradation
of the modified protein. Interestingly, although no connection
to protein stability has been established so far, the two best-
defined phosphorylation events (S80 and S421) reside in the
PEST domains. In addition to phosphorylation, authors have
identified several potential ubiquitination sites at lysine residues
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Table 2 | Post-translational modifications within MeCP2 other than phosphorylation.
Residue Mutation in RTT PTM Cell line/Tissue assayed References
K12 K12N (0.04%) Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
K82 K82fs (0.02%)
K82R (0.02%)
Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
K119 – Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
– Met 293 T Jung et al., 2008
K130 – Ub HEK-293T
SH-SY5Y neuroblast. cells
Wagner et al., 2011; Gonzales et al., 2012
K135 K135E (0.15%) Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
R162 R162fs (0.06%) Met Kidney (7945, 7947)
Lung (7946, 7948)
Mice brain
www.PhosphoSite.org (Hornbeck et al.,
2012), CST curation sets 7945, 7946, 7947,
7948, (Guo et al., 2014)
K210 K210I (0.02%) Met 293 T Jung et al., 2008
K223 K223NfsX3 (0.02%) SUMO Primary cortical neurons Cheng et al., 2014
K233 K233fs (0.02%) Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
K249 – Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
K256 K256SfsX17
(0.02%)
Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012




Ac SH-SY5Y neuroblast. cells Gonzales et al., 2012
K307 – Ac SH-SY5Y neuroblast. cells Gonzales et al., 2012
K321 K321Sfs*13 (0.02%) Ac SH-SY5Y neuroblast. cells Gonzales et al., 2012
Ub SH-SY5Y neuroblast. cells Gonzales et al., 2012
T436 – O-GlcNAc Murine synaptosomes (Trinidad et al., 2012)
Rat brain (Wang et al., 2010)
Wang et al., 2010; Trinidad et al., 2012
T442 T442fs (0.02%)
T442A (0.02%)
O-GlcNAc Rat brain Wang et al., 2010
K449 – Ac MV4-11 (Choudhary et al., 2009)
HCT 116 (CST)
(Choudhary et al., 2009)
www.PhosphoSite.org (Hornbeck et al.,
2012), CST curation sets 9796, 9797
K461 – Ac HEK-293 cells and primary cortical neurons (Zocchi and Sassone-Corsi, 2012)
flanking the PEST domains. The hypothesis that the two PEST
domains have a major role in fine-tuning MeCP2 levels and that
PTMs associated with the modification of these domains regulate
the activity of MeCP2 is a challenging one. However, no fur-
ther data have been provided to support it and evidence for the
ubiquitination of these residues is still lacking.
More recently, MeCP2 has been found modified by the cova-
lent linkage of small ubiquitin-like modifier (SUMO) to several
lysines. In particular, the sumoylation of lysine 223 is required for
the recruitment of HDAC1/2 complexes and mutation of K223
abolishes its gene silencing properties in primary cortical neu-
rons (Cheng et al., 2014). Furthermore, this mutation impacts
proper excitatory synaptogenesis in vitro and in vivo suggesting
the relevance of sumoylation for MeCP2 functions.
In addition, Mecp2 has been found acetylated in several
residues (Choudhary et al., 2009; Gonzales et al., 2012; Zocchi
and Sassone-Corsi, 2012); in particular, acetylation of K464
of Mecp2_e1 has been identified in cultured cortical neu-
rons. The authors have demonstrated that this modification
is mediated by p300 and erased by the nicotinamide-adenine
dinucleotide dependent histone deacetylase SIRT1. Chromatin
immunoprecipitation experiments performed in Sirt1-null mice
have led to hypothesize that K464 acetylation affects Mecp2 bind-
ing to DNA. However, in this work only the BDNF promoter has
been tested.
Finally, MeCP2 has been found methylated in 293T cells (Jung
et al., 2008) and O-glycosylated in 293T cells and rat brain
(Rexach et al., 2010). For convenience, we provide a table sum-
marizing the residues of MeCP2 that have been found involved in
PTMs different from phosphorylation (SI Table 2). In this table,
as well as in SI Table 1, we show the cell line/tissue in which
the PTM was identified, the corresponding references, and the
possible association of the residue involved with Rett syndrome.
Few modified residues of MeCP2 have been linked to patholog-
ical conditions and with a very low incidence: thus, so far it is
impossible to draw any genotype-phenotype correlation.
To conclude, the studies reviewed strengthen the hypothesis
that a complex combinatorial pattern of PTMs functions as a reg-
ulatory platform of the methyl-binding protein. Once again the
RTT field is awaiting the discovery of the functional consequences
of these PTMs and their combinations. Their role in regulating
synaptic plasticity is of special interest since deficits in MeCP2 has
Frontiers in Cellular Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 236 | 11
Bellini et al. MeCP2 post-translational modifications
a strong impact on synaptic functions. Finally, the identification
of their possible “readers,” as well as of effecting enzymes (“writ-
ers”) and their possible involvement in MECP2 related disorders
represent urgent challenges.
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